Evaluating the safety, effectiveness and acceptability of treatment of incomplete second-trimester abortion using misoprostol provided by midwives compared with physicians: study protocol for a randomized controlled equivalence trial. by Atuhairwe, Susan et al.
LSHTM Research Online
Atuhairwe, Susan; Byamugisha, Josaphat; Klingberg-Allvin, Marie; Cleeve, Amanda; Hanson, Clau-
dia; Tumwesigye, Nazarius Mbona; Kakaire, Othman; Danielsson, Kristina Gemzell; (2019) Evalu-
ating the safety, effectiveness and acceptability of treatment of incomplete second-trimester abortion
using misoprostol provided by midwives compared with physicians: study protocol for a randomized
controlled equivalence trial. TRIALS, 20 (1). ISSN 1745-6215 DOI: https://doi.org/10.1186/s13063-
019-3490-5
Downloaded from: http://researchonline.lshtm.ac.uk/4653678/
DOI: https://doi.org/10.1186/s13063-019-3490-5
Usage Guidelines:
Please refer to usage guidelines at https://researchonline.lshtm.ac.uk/policies.html or alternatively
contact researchonline@lshtm.ac.uk.
Available under license: http://creativecommons.org/licenses/by/2.5/
https://researchonline.lshtm.ac.uk
STUDY PROTOCOL Open Access
Evaluating the safety, effectiveness and
acceptability of treatment of incomplete
second-trimester abortion using
misoprostol provided by midwives
compared with physicians: study protocol
for a randomized controlled equivalence
trial
Susan Atuhairwe1,2* , Josaphat Byamugisha1, Marie Klingberg-Allvin3,4,5, Amanda Cleeve3,4, Claudia Hanson6,7,
Nazarius Mbona Tumwesigye8, Othman Kakaire1 and Kristina Gemzell Danielsson3,4
Abstract
Background: A large proportion of abortion-related mortality and morbidity occurs in the second trimester of
pregnancy. The Uganda Ministry of Health policy restricts management of second-trimester incomplete abortion to
physicians who are few and unequally distributed, with most practicing in urban regions. Unsafe and outdated
methods like sharp curettage are frequently used. Medical management of second-trimester post-abortion care by
midwives offers an advantage given the difficulty in providing surgical management in low-income settings and
current health worker shortages. The study aims to assess the safety, effectiveness and acceptability of treatment of
incomplete second-trimester abortion using misoprostol provided by midwives compared with physicians.
Methods: A randomized controlled equivalence trial implemented at eight hospitals and health centers in Central
Uganda will include 1192 eligible women with incomplete abortion of uterine size > 12 weeks up to 18 weeks. Each
participant will be randomly assigned to undergo a clinical assessment and treatment by either a midwife
(intervention arm) or a physician (control arm). Enrolled participants will receive 400 μg misoprostol administered
sublingually every 3 h up to five doses within 24 h at the health facility until a complete abortion is confirmed.
Women who do not achieve complete abortion within 24 h will undergo surgical uterine evacuation. Pre discharge,
participants will receive contraceptive counseling and information on what to expect in terms of side effects and
signs of complications, with follow-up 14 days later to assess secondary outcomes. Analyses will be by intention to
treat. Background characteristics and outcomes will be presented using descriptive statistics. Differences between
groups will be analyzed using risk difference (95% confidence interval) and equivalence established if this lies
between the predefined range of − 5% and + 5%. Chi-square tests will be used for comparison of outcome and t
tests used to compare mean values. P ≤ 0.05 will be considered statistically significant.
(Continued on next page)
© The Author(s). 2019 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
* Correspondence: atususan96@gmail.com
1Department of Obstetrics and Gynecology, Makerere University, Kampala,
Uganda
2Mulago National Referral Hospital, Kampala, Uganda
Full list of author information is available at the end of the article
Atuhairwe et al. Trials          (2019) 20:376 
https://doi.org/10.1186/s13063-019-3490-5
(Continued from previous page)
Discussion: Our study will provide evidence to inform national and international policies, standard care guidelines
and training program curricula on treatment of second-trimester incomplete abortion for improved access.
Trial registration: ClinicalTrials.gov, NCT03622073. Registered on 9 August 2018.
Keywords: Post abortion care, Misoprostol, Second trimester, Task sharing, Incomplete abortion, Contraception,
Uganda,
Background
Globally, 303,000 maternal deaths occurred in 2015 [1],
with 11% of maternal deaths and a large number of mor-
bidities attributable to consequences of unsafe abortion
[2–4]. More than 97% of unsafe abortions occur in sub-
Saharan Africa, with the rates of unplanned pregnancy
ending in an abortion increasing in low-income settings
while decreasing in high-income countries [4]. Reasons
behind the high unsafe abortion rates in low-income set-
tings are restrictive abortion laws, high unmet need for
contraception and low women’s status [3, 5].
Post-abortion care (PAC), defined as the comprehen-
sive treatment of women presenting after spontaneous
or induced, safe or unsafe abortion, is an effective inter-
vention to decrease maternal mortality globally [6]. PAC
comprises five key elements: emergency treatment, fam-
ily planning, counseling, other reproductive and related
health services, and community–service provider part-
nerships [7]. Evidence shows that PAC services can be
safely offered by midwives in the first trimester [8, 9].
Evidence is lacking on whether PAC can also be safely
offered by midwives in the second trimester particularly
in rural settings of low-income countries where physi-
cians are scarce, such as Uganda.
Uganda has a high total fertility rate (5.4 children per
woman), a low contraceptive prevalence rate of 39% and
an unmet need for contraception of 28% [10]. More than
half of all pregancies are unintended due to insufficient
knowledge of and misinformation about contraception,
inaccessibility to family planing services and ineffective
contraceptive use [11]. Multiple obstacles to contracep-
tive use, such as misconceptions and fears related to
contraception, gender–power relations, sociocultural
factors and health care service barriers have been cited
[12, 13]. Induced abortion in Uganda is restricted and le-
gally permitted only to save a woman’s life [14]. As a re-
sult, women often resort to unsafe abortion “that’s either
performed by a person lacking the necessary skills or in
an environment that does not conform to minimal med-
ical standards” [6]. Of the estimated 314,304 women
who undergo unsafe abortions each year, about 128,682
experience complications with only 85,000 obtaining
care [15]. Consequently, it is estimated that complica-
tions from spontaneous and unsafe abortions contribute
to 8% of maternal mortality in Uganda [16]. Post-
abortion complications are exacerbated by lack of re-
sources, delayed care-seeking and harmful abortion
practices [17]. In some instances, women will fear acces-
sing care due to stigma that is intrinsic, or from family
members, community providers and even health pro-
viders [18]. Although abortion in Uganda is restricted,
treatment of post-abortion complications is a critical
component of emergency obstetric care services offered
throughout the spectrum of health facilities from Health
Centre IIs to hospitals [19, 20]. A study in 2014 cited
midwives as the main implementers of PAC in the first
trimester, often only consulting a physician when a com-
plication arises [21].
Low-income countries like Uganda suffer from short-
ages and an unequal distribution of trained health care
providers. Almost two thirds of all physicians work in
the urban regions, which serve less than one third of the
population [20]. While the Ministry of Health (MOH)
policy in Uganda allows both physicians and midwives
to treat women with first-trimester incomplete abor-
tions, it restricts management of second-trimester in-
complete abortion to physicians [19]. The standard
treatment for bleeding following an abortion in the first
trimester is either misoprostol or manual vacuum aspir-
ation, while sharp curretage by a doctor is done for
women in the second trimester. The need for a surgical
intervention in a setting where there is a scarcity of
trained providers, sterile equipment and poor access to
high-level centers limits women’s access to safe PAC, es-
pecially in remote areas. Observations in clinical practice
show that the number of incomplete abortions in the
second trimester are at least as high as in the first tri-
mester in Uganda.
Evidence is compelling that the prostaglandin E1
analogue misoprostol is effective medication for first-
trimester incomplete abortions [8, 22], and that there is
no difference whether provided by physicians or mid-
wives [8, 23, 24]. The choice of an equivalence trial de-
sign is to provide evidence that use of misoprostol for
PAC in the second trimester when administered by phy-
sicians or midwives is equally safe, effective and accept-
able. In view of the severe shortage of medical staff in
rural areas and importance of task sharing to improve
productivity and efficiency within a health system [21,
25, 26], the overall aim of the study is to compare the
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safety, effectiveness and acceptability outcomes of treat-
ment for incomplete abortion using misoprostol when
provided by midwives versus physicians in Uganda.
Methods
Trial design
The study uses a multicenter randomized controlled
equivalence design to compare the management of
second-trimester abortion complications with misopros-
tol to be provided by a midwife or a doctor in a ratio of
1:1 (Fig. 1). The trial follows recommendations of the
modified Consort guidelines for equivalence trials [27]
and the Helsinki Declaration [28]. A populated Standard
Protocol Items: Recommendations for Interventional
Trials (SPIRIT) checklist is provided in Additional file 1.
Study setting
The study is implemented in the central region of
Uganda, which has a higher estimated induced abortion
rate compared to the national average (52 versus 39 per
1000 live deliveries) and an accompanying huge caseload
of women treated for abortion complications [29]. All
selected study sites are public health facilities, equipped
to provide comprehensive emergency obstetric services
in rural, peri-urban and urban areas. They comprise
Health Centre IVs (the lowest health care level staffed
with both physicians and midwives), district hospitals
and a regional referral hospital, all located within 1–2 h
from Kampala, the capital city of Uganda.
Health facilities identified for inclusion in the trial
have an average caseload of about 90 women with
Fig. 1 Trial design. ITT intention to treat
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incomplete second-trimester abortions per month and
sufficient staff to establish a group of 138 midwives plus
other nurse-midwifery cadres at certificate, diploma and
degree level and 37 physicians based on mapping of fa-
cility records data for January–June 2017, done by one
of the researchers (SA). Hospital-based study sites have
an average (median) of 5 (6) physicians and 19 (20) mid-
wives, whereas the Health Centre IV study sites have an
average (median) of 3 (3) physicians and 13 (16) mid-
wives. We assume that these staff will provide an ad-
equate pool of health providers to conduct the study.
The cadre of physicians consist of medical officers and
obstetricians/gynecologists with 5 years of medical train-
ing and an additional 3 years postgraduate training, re-
spectively. Nursing and midwifery preservice programs
in Uganda offer certificate, diploma or degree qualifica-
tions after 18 months, 3 years and 4 years of training, re-
spectively. Competences are most often in midwifery
and nursing, and there is provision for upgrading to a
higher qualification with additional training. In this trial,
a midwife is defined as a health provider who has ob-
tained midwifery training competence as part of their
preservice or additional training program.
Eligibility criteria
Women with abortion complications presenting with va-
ginal bleeding, uterine contractions, uterine size more
than 12 weeks but no more than 18 weeks by palpation,
history of partial expulsion and an open cervical os will
be included in the study. We will exclude women with
known age younger than 15 years, allergy to misoprostol,
unstable hemodynamic status (systolic blood pressure <
90mmHg) and shock, signs of pelvic infection and/or
sepsis, previous caesarean delivery/uterine scar, sus-
pected extra-uterine pregnancy, perforation of the
uterus, injury to the surrounding organs, heavy vaginal
bleeding, severe abdominal pain, cervical tear, uterine
size ≤12 or > 18 weeks, temperature greater than 38 °C
and current molar abortion.
Recruitment
The study aims to recruit 50 eligible patients monthly
over a 24-month period. The health facility staff in all
potential recruitment areas, including maternity wards,
female wards, emergency wards and outpatient clinics,
will be sensitized about the study and encouraged to
alert the study team members when a probable case is
identified. Notices/posters indicating brief study details
and contact persons will be placed at potential recruit-
ment sites of the facility as reminders to staff. All partic-
ipants are given a modest transport reimbursement of
UGX 10,000 (USD 3) for follow-up visits.
Interventions
Enrollment
All women presenting with signs of an incomplete abor-
tion are screened for eligibility by a trained midwife
using a predefined checklist. The research assistant ob-
tains written informed consent through a process that
involves: giving the participant information concerning
the study; providing adequate opportunity for the par-
ticipant to consider all options; responding to the partic-
ipant’s questions; ensuring that the participant
comprehends this information; obtaining the partici-
pant’s voluntary agreement to participate; and continu-
ing to provide information as the participant or situation
requires. Women excluded at this point are registered
and the reason for exclusion indicated.
Procedure
All assessment and care are provided in a way that en-
sures privacy and confidentiality. Eligible women who
consent undergo a clinical assessment by either a mid-
wife (intervention arm) or a physician (control arm).
The clinical assessment includes: history taking (sociode-
mographic information, last menstrual period (LMP), as-
sessment for chronic medical conditions, obstetric and
gynecological history, previous use of contraception and
details of presenting symptoms); general physical exam-
ination and vital signs (pulse, blood pressure and
temperature); and abdominal examination to assess the
size of the uterus and a vaginal examination to assess
cervical opening, bleeding and signs of genital infections.
The World Health Organization (WHO), in their 2012
safe abortion technical and policy guidance, recommend
that the misoprostol regimen for second-trimester ter-
mination of pregnancy [6] can be used for incomplete
abortion management: 400 μg misoprostol sublingual
every 3 h up to five doses. Each treatment dose consists
of two 200 μg tablets of misoprostol administered sub-
lingually by the allocated health care provider and this is
repeated every 3 h for a maximum of five doses or until
a complete abortion is confirmed. The allocated health
provider to whom a woman is randomized assesses for
presence of side effects, vaginal bleeding and uterine
contractions, measures blood pressure and pulse and
also records any medication given at 3-h intervals before
the next dose of misoprostol is given. The participant
completes the full course of treatment under direct ob-
servation while at the health facility to ensure adherence.
When the participant reports an expulsion, a health pro-
vider in the allocated arm performs a clinical assessment
to diagnose a complete abortion and records the time of
completion, and an independent assessor verifies that
the main outcome has been achieved. The expelled
products of conception are examined to ascertain the
type, whether placental tissue only or whole fetus and
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placental tissue. All women receive oral nonsteroidal
anti-inflammatory drugs starting when the first dose of
misoprostol is administered and prophylactic oral antibi-
otics – amoxicillin 500 mg and metronidazole 400 mg
every 8 h for 5 days [30].
In the case that no complete abortion has been
achieved within 24 h from the time the first dose of mi-
soprostol was administered, a doctor performs a surgical
method of uterine evacuation using MVA or blunt curet-
tage. Patients can also be discontinued from medical
management and surgical management instituted if their
condition worsens during treatment or on request. All
participants are discharged 4 h after completing the
abortion if there are no complications. Before discharge,
women receive detailed information regarding abnor-
mal symptoms (fever, foul smelling vaginal discharge,
bleeding and pain), when to seek care, and contracep-
tive counselling and provision, and advised to return
for a follow-up visit 14 days after treatment. A de-
tailed description of the study participant timeline is
provided in Fig. 2.
Outcomes
The primary outcome is complete abortion requiring no
surgical intervention within 24 h of initiating treatment.
A 24-h timeframe was chosen for clinical relevance
given that the participants will be monitored at the
health facility. Clinical assessment for the primary out-
come includes physical and pelvic examination with at-
tainment of a complete abortion based on cessation of
uterine cramps and vaginal bleeding and a closed cer-
vical os. An ultrasound scan is not used to diagnose a
complete abortion, given its low predicting value to indi-
cate the need of additional surgical intervention. Ultra-
sound scan measurement of endometrial thickness as an
indicator of a complete abortion actually biases toward
increased surgical interventions without significantly im-
proving patient outcomes [31].
Secondary outcomes are assessed at the 2-week
follow-up visit and include: excessive vaginal bleeding,
defined as soaking more than three pads in an hour; ab-
dominal pain, defined as discomfort experienced in the
lower abdomen and intensity measured using a visual
Fig. 2 Standard Protocol Items: Recommendations for Interventional Trials figure—participant enrolment and follow-up. PAC post-abortion care
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analogue scale with a minimum score of 0 representing
no pain and a maximum score of 10 representing most
pain; unscheduled visits, defined as participants present-
ing at the study site when not expected, need for add-
itional medical treatment and experience of misoprostol
side effects; sepsis, defined as presence of fever with
temperature greater than 38 °C, pus or offensive vaginal
discharge; time from induction (first dose of misopros-
tol) to completion and total dose of misoprostol given;
women’s acceptability of the PAC provider with accept-
ability defined as positive reporting of treatment experi-
ence, recommendation of method to a friend or reuse of
same method; and contraceptive uptake and discontinu-
ation over a period of 1 year.
Data collection methods
The information on history, enrolment, procedures and
outcomes is collected using an interviewer-administered
pretested structured questionnaire and structured clin-
ical notes. All health workers undertake a standardized
2-day training in misoprostol use for management of in-
complete abortion and study procedures. Key areas in
the training content include: making a diagnosis of in-
complete abortion, use of misoprostol for uterine evacu-
ation, pain relief, post-abortion counseling and values
clarification, contraceptive counselling and provision,
study procedures, adverse event reporting, danger signs
and management of complications. Evaluation of train-
ing is done using pre and post knowledge assessments.
All research assistants also receive training on research
conduct prior to the study. Key areas covered include:
research ethical principles, informed consent process,
data collection and storage procedures and strategies for
retention of study participants. All investigators are
trained in good clinical practice. The strategies imple-
mented to promote retention in the study include:
clearly informing participants of the study procedure
and follow-up schedule, assessing the main outcome be-
fore discharge, giving specific follow-up review dates and
obtaining at least two phone contacts to ensure commu-
nication for follow-up. We conduct continuous process
evaluation to ascertain reasons for loss to follow-up,
identify and implement context-specific mitigating ac-
tions and, in addition, record and analyze reasons for
nonadherence or nonretention in the study.
Sample size
The sample size has been calculated with the objective
of establishing the equivalence of misoprostol treatment
of incomplete abortion provided by midwives compared
with physicians, in terms of the percentage of women
not requiring back-up surgical treatment. PASS software
version 14 was used for sample size computations for
equivalence studies, at a power of 80%, two-sided CI of
95%, set actual difference D1 range of − 5% to + 5%,
smallest difference of 0.001, design effect = 1 and 5%
level of significance of results [32]. If a second-trimester
abortion treated with misoprostol 400 μg every 6 h ad-
ministered vaginally has an effectiveness of 90% at 48 h,
we assume that the same dose used every 3 h sublin-
gually for second-trimester incomplete abortion would
have around 90% effectiveness at 24 h given the faster
onset of action for the sublingual route [33]. If both allo-
cation arms have the same success rates within an
equivalence margin of 10%, then 566 women will be re-
quired in each arm. Considering a loss to follow-up of
5%, 1192 women will be recruited for the study. Table 1
presents the various sample size scenarios, with a δ value
of 5% and power of 80% chosen based on the feasibility
of accruing the sample size.
Random allocation
A computer-generated blocked randomization was done
by the statistician to generate a randomization list strati-
fied for each study site. The randomization ratio is 1:1
for physicians versus midwives in random blocks of 4–
12. The block sizes are not disclosed to the research as-
sistants to ensure concealment. Allocation is concealed
using sealed, opaque, sequentially numbered envelopes
each containing a serial number and unique study num-
ber showing the allocation arm for the individual
woman. The randomization list will remain with the
statistician throughout the duration of the study and the
trial investigators as well as research assistants will not
have access to it. Process evaluation is carried out using
intermittent check-ups to ensure that the protocol inter-
vention procedures are performed correctly.
Blinding
Given the nature of the study, the health providers and
participants cannot be blinded to the study allocation
arm once randomization has occurred. The main out-
come assessment is confirmed by an independent asses-
sor who is blinded to the participant’s allocation arm to
reduce bias. The data entrants will be blinded to the al-
location groups. The Data Safety Monitoring Board
(DSMB) will initially be blinded as they conduct the in-
terim analysis, and only unblinded if any safety issues
emerge.
Table 1 Sample size scenarios
δ (%) Power = 80% Power = 90%
4 884 (1768) 1183 (2366)
5 566 (1132) 757 (1514)
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Data management
Data are collected at the study sites in paper case record
forms (CRFs) and stored in numerical order in a box file at
a secure place. The study coordinator or principal investiga-
tor conducts biweekly visits at each of the sites to verify
each form for completeness and accuracy. At this point,
any missing or inaccurate information is rectified and the
checked completed forms brought to the central coordinat-
ing center for data entry. Data are double entered into the
Epidata version 3.1 study-team-approved soft-copy tool.
Provisions (Data Monitoring Plan) have been inserted to
check for missing data, with predefined ranges, ensuring
use of the correct data format and standardized codes. Any
changes (based on discrepancies identified on further clean-
ing) made to data already entered are only done by autho-
rized personnel and a monthly report indicating the errors
cited and corrections made is filed with the project steering
committee. Cross-referencing is done with the paper form
to ensure completeness of the query correction. A statisti-
cian will be involved in analysis of the results.
Statistical methods
Statistical analysis will be done using Stata version 13. All
analyses will be by intention-to-treat (ITT) supplemented
by per-protocol analysis. Background characteristics for
the two study groups will be described. Categorical data
will be presented as proportions and continuous data as
means and standard deviations. To determine the differ-
ences in background characteristics, chi-square tests will
be used for categorical data and Student t tests for con-
tinuous data. Analysis of the primary outcome between
groups will be done using risk difference with 95% confi-
dence intervals and equivalence established if it lies be-
tween the predefined range of − 5% and + 5%. P ≤ 0.05
will be considered statistically significant. Chi-square tests
will be used for comparison of outcomes and Student’s t
tests used to compare mean values. Comparisons of side
effects will be carried out using Fisher’s exact tests.
We will use a generalized linear mixed-effects model
with the provider as a fixed effect and the health care fa-
cility as a random effect. This will allow us, to some ex-
tent, to take into account differences in performance
between the sites. Time to completion of abortion will
be computed and analyzed using standard survival ana-
lysis techniques. Participants will be censored at the time
that the main outcome, a complete abortion, is docu-
mented or at 24 h if no complete abortion is achieved.
Time in this study will be computed in hours. Median
times to completion will be derived from Kaplan–Meier
estimates of the survival function and the groups will be
compared using the log-rank test. Further analysis will
be carried out using a Cox proportional hazards model,
which establishes factors associated with time to
complete abortion in a multivariable model.
Data monitoring
A group of independent experts with different compe-
tences will form a DSMB in order to monitor patient
safety and treatment efficacy data while the randomized
control trial is ongoing. The board will periodically, at
its discretion, review the trial outcome data by the study
group plus any other information required and make
recommendations to the steering committee. None of
the board members is involved in the study implementa-
tion or funding of the study. The steering committee is
composed of trial investigators as per the title page and
two independent members, and chaired by the Head of
Department Obstetrics and Gynaecology, Makerere Uni-
versity, Kampala.
Since safety is one of the main issues under study, an
interim analysis for safety profile will be done by an in-
dependent statistician blinded for treatment allocation
when 50% of the data have been collected and entry
done. The results will be shared with the DSMB, who
will then have a discussion with the steering committee
who decide on the continuation of the trial. Annual pro-
gress reports are submitted to the Institutional Review
Board (IRB) and Uganda National Council for Science
and Technology (UNCST) ethical bodies and protocol
amendments made if indicated. The trial will not be
stopped in case of futility, unless the DSMB advises
otherwise and approved by the steering committee. The
funders will not have access to the trial data to avoid
bias from competing interests.
Harms
Categories of serious adverse events (SAEs) in this study
include death, disability/incapacity, life-threatening sep-
sis, hospitalization longer than 48 h and blood transfu-
sion for severe hemorrhage. A SAE will be considered
unexpected if it is not described in the protocol. SAEs
will be recorded as study related only if the participant
has signed the consent form and started the interven-
tion. These events will be recorded throughout the time
the participant is admitted to the health facility. SAEs
occurring after the participant has completed the first
follow-up visit will not be reported unless the principal
investigator feels that the event may have been caused
by the protocol procedure. The PI will promptly inform
the institutional review board if a SAE occurs. In the
case of physical injury resulting from participation in the
study, participants will receive medical treatment at a
public health facility until resolution or stabilization.
Confidentiality
Data tools and instruments are stored securely and ac-
cess restricted to authorized study team members. The
computer used for data storage is password protected.
Any results retrieved for interim analysis and monitoring
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purposes will be password protected and restricted to
authorized study team members. Collected data will be
backed up on monthly basis and securely stored for a
period not exceeding 7 years.
Dissemination plan
The research team will simplify the study findings and
disseminate to the community through local media out-
lets. Presentations will be made at the Ministry of Health
through national Technical Working Group meetings to
inform policy-makers. We will publish in international
scientific peer-reviewed journals and present at inter-
national conferences.
Discussion
The present research study intends to explore the topics
of interest in a coherent and systematic way. The long-
term goal of this study is to provide evidence-based in-
formation that will contribute to the development of
strategies to increase women’s access to safe PAC in
low-income contexts where diagnosis and services are
constrained. This evidence will provide information to
policy-makers in Uganda about women’s reproductive
health needs related to availability and improvements in
PAC, as well as counseling and contraception for all
women. By evaluating the safety and effectiveness of
midwives administering misoprostol for treatment of
second-trimester incomplete abortion, whose manage-
ment is currently restricted to physicians, the study is
attempting to contribute to the reduction of maternal
morbidity and mortality and to mitigate human resource
problems in emergency obstetric and gynecological care.
A direct economic impact can also be expected due to
reduced treatment costs of complications from incom-
plete abortions.
Limitations
The study is implemented at study sites with variable cli-
ent caseloads due to the differing levels of health care
provision. We have addressed this using blocked
randomization to cater for the uneven number of partic-
ipants from each site. The health care providers to
whom women are randomized work closely at the clinic
and within the same environment, which might affect
the outcome. Health care providers’ years of working ex-
perience might differ between the two groups of mid-
wives and doctors and by individual. Most commonly,
midwives working in rural area have longer work experi-
ence than doctors. In addition, the health provider’s indi-
vidual attitude and experiences of using misoprostol
might further impact the outcome. All health providers
at the participating health facilities will undergo stan-
dardized training to strengthen the internal validity.
Trial status
Protocol version number: PACII 01, issued 17 November
2017. Participant recruitment began on 14 August 2018,
and the approximate date recruitment will be completed
is 15 August 2020.
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